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Cerebral White Matter Hyperintensities, Kidney Function
Decline, and Recurrent Stroke After Intensive Blood Pressure
Lowering: Results From the Secondary Prevention of Small
Subcortical Strokes (SPS3) Trial
Jesse C. Ikeme, MD; Pablo E. Pergola, MD, PhD; Rebecca Scherzer, PhD; Michael G. Shlipak, MD, MPH; Luciana Catanese, MD;
Leslie A. McClure, PhD, MS; Oscar R. Benavente, MD; Carmen A. Peralta, MD, MAS
Background-—We aimed to determine whether cerebral white matter hyperintensities (WMHs) can distinguish stroke survivors
susceptible to rapid kidney function decline from intensive blood pressure (BP) lowering.
Methods and Results-—The SPS3 (Secondary Prevention of Small Subcortical Strokes) trial randomized participants with recent
lacunar stroke to systolic BP targets of 130 to 149 and <130 mm Hg. We included 2454 participants with WMH measured by
clinical magnetic resonance imaging at baseline and serum creatinine measured during follow-up. We tested interactions between
BP target and WMH burden on the incidence of rapid kidney function decline (≥30% decrease from baseline estimated glomerular
filtration rate at 1-year follow-up) and recurrent stroke. Rapid kidney function decline incidence was 11.0% in the lower-BP-target
arm and 8.1% in the higher-target arm (odds ratio=1.40; 95% CI=1.07–1.84). Odds ratio for rapid kidney function decline between
lower- and higher-target groups ranged from 1.26 in the lowest WMH tertile (95% CI, 0.80–1.98) to 1.71 in the highest tertile (95%
CI, 1.05–2.80; P for interaction=0.65). Overall incidence of recurrent stroke was 7.9% in the lower-target arm and 9.6% in the
higher-target arm (hazard ratio=0.80; 95% CI, 0.63–1.03). Hazard ratio for recurrent stroke in the lower-target group was 1.13 (95%
CI, 0.73–1.75) within the lowest WMH tertile compared with 0.73 (95% CI, 0.49–1.09) within the highest WMH tertile (P for
interaction=0.04).
Conclusions-—Participants with higher WMH burden appeared to experience greater benefit from intensive BP lowering in
prevention of recurrent stroke. By contrast, intensive BP lowering increased the odds of kidney function decline, but WMH burden
did not significantly distinguish this risk.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00059306. ( J Am Heart Assoc. 2019;8:
e010091. DOI: 10.1161/JAHA.118.010091.)
Key Words: blood pressure • creatinine • estimated glomerular filtration rate • kidney • lacunar stroke • secondary prevention
of small subcortical strokes • white matter disease
T he ideal blood pressure (BP) target for prevention ofrecurrent stroke remains an issue of active discussion.
New hypertension guidelines recommend a target systolic BP
(SBP) of<130 mm Hg in this population.1 The SPS3 (Secondary
Prevention of Small Subcortical Strokes) randomized trial
demonstrated that BP lowering to <130 mm Hg, compared
with 130 to 149 mm Hg, significantly reduced the risk for
intracerebral hemorrhage by 60%, but the 19% reduction in all
stroke recurrence failed to reach statistical significance.2 On
the other hand, there is great concern that aggressive BP
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lowering can result in large decreases in kidney function,
measured by estimated glomerular filtration rate (eGFR). Higher
rates of kidney function decline and acute kidney injury with
intensive BP lowering have been demonstrated in SPS3 as well
as in other large, randomized trials of BP lowering for primary
cardiovascular disease prevention.3–5
The clinical significance of such decreases in kidney
function remains an issue of active investigation. Observa-
tional data show that decreases in eGFR are strongly
associated with higher end-stage renal disease risk.6 In a
clinical trial setting, even small decreases in eGFR from
intensive BP lowering were associated with progression to
end-stage renal disease.7 On the other hand, previous
reports from SPS3 and SPRINT (Systolic Blood Pressure
Intervention Trial) showed that decreases in eGFR that are
specific to the setting of intensive BP lowering may not
portend increased risk for further kidney injury or adverse
cardiovascular events, but, rather, they represent a hemo-
dynamic phenomenon.5,8 Many experts remain concerned
that associations of even small increases in creatinine after
intensive BP lowering with poor renal outcomes raise
concern for ongoing ischemic injury.7,9 The best strategy
for identifying persons at highest risk for kidney function
decline with intensive BP lowering is unknown. It is possible
that kidney function decline from intensive BP lowering is a
result of impaired small-vessel autoregulation in the kidney.
This would imply that persons with greater severity of small
vessel disease may be at higher risk for kidney function
decline from intensive BP lowering. On the other hand, given
that these patients are likely at higher risk of cardiovascular
events, they may also derive the most benefit from intensive
BP lowering.10
White matter hyperintensities (WMHs) are thought to be
markers of small vessel disease in the brain.11 WMHs are
known to have higher prevalence in the setting of
hypertension and advanced age. They have also been
associated with increased risk of stroke-impaired autoreg-
ulation of cerebral vasculature.10,12,13 Given the anatomical
and vasoregulatory similarities between the brain and
kidney and the known association between WMHs and
chronic kidney disease,14,15 we hypothesized that those
with greater burden of WMHs likely have corresponding
small-vessel disease in the kidney. Consequently, they
could be at higher risk of rapid decreases in eGFR after
intensive BP lowering. To date, such a relationship has not
been investigated.
We conducted a secondary analysis of the SPS3 random-
ized trial to determine whether the presence of WMHs could
identify participants at highest risk of kidney function decline
from intensive BP lowering. Given that persons with high
WMH burden are at higher risk for stroke recurrence, we were
also interested in understanding whether these persons may
also derive more benefit from intensive BP lowering for
secondary prevention of stroke.
Methods
Study Design
The SPS3 trial was a 292 factorial trial that randomized
participants with recent lacunar stroke to evaluate the effect
of an intensive BP target of <130 mm Hg compared with SBP
130 to 149 mm Hg for the prevention of recurrent stroke.16
Participants were also randomized to an antiplatelet regimen
of aspirin and clopidogrel or aspirin and placebo. The BP trial
was open label using the PROBE (prospective randomized
open blinded end-point) study design.17 Details of the trial
design have been published.16 The study is registered on
ClinicalTrials.gov under NCT00059306.
Participants
The SPS3 trial enrolled 3020 patients with recent lacunar
stroke. Patients with eGFR <40 mL/min/1.73 m2 were
excluded from enrollment. After randomization to an anti-
platelet arm and a BP arm, participants were followed at least
once per month until achievement of the assigned target BP,
then every 3 months for a mean of 3.7 years. In our cross-
sectional analysis and our analysis of recurrent stroke, we
excluded 53 participants. Fifty of these participants had no
WMH score; 3 participants had no creatinine measure at
baseline, leaving a total of 2967 participants available for
analysis. Our longitudinal analysis of kidney outcomes
excluded an additional 513 participants missing a serum
creatinine measure at 1 year after randomization, leaving
2454 included participants. All participants signed informed
consent, and the trial was approved by all appropriate
institutional review boards.
Clinical Perspective
What Is New?
• Among survivors of lacunar stroke, persons with high white
matter hyperintensity burden are most likely to benefit from
intensive blood pressure control to prevent recurrent stroke.
• White matter hyperintensity burden did not significantly
distinguish risk of kidney function decline after intensive
blood pressure lowering.
What Are the Clinical Implications?
• White matter hyperintensities may contribute to the
assessment of the benefit and harm of intensive blood
pressure control after lacunar stroke.
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Kidney Function
We estimated kidney function from serum creatinine measures
using the CKD-EPI (Chronic Kidney Disease Epidemiology
Collaboration) equation.18 Serum creatinine measures were
obtained from all SPS3 participants at a prerandomization visit
and annual follow-up visits until the study end date.16
Neuroimaging
Patients underwent magnetic resonance imaging for clinical
management when presenting with the index stroke or
recurrent stroke. WMHs were evaluated visually on fluid-
attenuated inversion recovery images using the Age-Related
White Matter Changes, or Wahlund, scale by 4 readers
unaware of clinical information.19 This semiquantitative scale
rates WMH severity from 0 to 3 in 5 predefined areas of each
brain hemisphere for a total possible range of 0 to 30.20 Inter-
rater agreement among readers was good to excellent on a
sample of 40 magnetic resonance imagings: (Cohen’s
kappa=0.64–0.89; 77–89% agreement).
Intervention
Participants were randomized at least 2 weeks after index
stroke to open-label SBP targets of 130 to 149 or
<130 mm Hg. Randomization was stratified by clinical center
and baseline hypertensive status and had a permuted-block
design with variable block size. Details regarding BP mea-
surement have been published previously.16
Outcomes
Our primary outcome of interest was incidence of rapid
kidney function decline, defined as a reduction in eGFR equal
to or greater than 30% between the visit before randomiza-
tion and the visit 1 year afterward. We focused on the first
year after randomization because this was the period of
medication intensification, as we have published.5 We also
analyzed the mean change in eGFR during the first year of
follow-up as a secondary kidney outcome. Finally, as a
secondary outcome of interest, we analyzed the SPS3
primary end point of all stroke to contextualize the risk for
rapid kidney function decline with the relative reduction in
stroke risk from aggressive BP lowering. This included
ischemic stroke, defined as a focal neurological deficit
persisting for longer than 24 hours with an absence of
hemorrhage, and intracranial hemorrhage, defined by hem-
orrhage in intracerebral, subdural, epidural, or subarachnoid
locations on neuroimaging. Strokes were identified and
adjudicated by board-certified neurologists blinded to
assigned SBP target and achieved BP. Other details on
outcome adjudication have been published.16
Covariates
Clinical and demographic characteristics were compared at
baseline and included in multivariable models. These included
age, sex, and race; smoking status, SBP, body mass index,
total cholesterol, high-density lipoprotein cholesterol, self-
reported history of diabetes mellitus or previous lacunar
stroke, hypertension, use of statins, use of antihypertensive
medications, and, separately, use of angiotensin converting
enzyme inhibitors or angiotensin receptor blockers. Hyper-
tension was defined as an average prerandomization SBP
greater than 140 mm Hg or a definite history of hypertension
being treated with an antihypertensive.
Statistical Analysis
First, we summarized baseline clinical and demographic
characteristics of participants by WMH score tertile. Differ-
ences in distribution of categorical variables and means of
continuous variables were tested using the chi-squared and
ANOVA tests, respectively.
Next, we estimated the associations of WMH score with
baseline kidney function. This was done using unadjusted and
multivariable adjusted linear regression.
Then, to evaluate the association of WMHs with 1-year
kidney function decline, we compared incidence of rapid
kidney function decline and mean 1-year kidney eGFR decline
in higher versus lower BP arms, stratified by tertile of WMHs.
We tested for interaction between BP target and WMH score
using logistic regression for the binary outcome of rapid
kidney function decline and linear regression for the contin-
uous outcome of 1-year change in kidney function.
We assessed whether WMH burden modified the effect of
intensive BP lowering on recurrent stroke by stratification
according to WMH tertile and interaction analyses using Cox
proportional hazards models for the SPS3 primary outcome of
recurrent stroke.
All analyses were conducted using the Stata (version 14.1;
StataCorp LP, College Station, TX) statistical software pack-
age. The data, analytical methods, and study materials are
available to other researchers upon request for purposes of
reproducing the results or replicating the procedure.
Results
Baseline Characteristics
Among the 2967 participants included in our cross-sectional
and recurrent stroke analyses, mean age was
62.810.8 years with a mean eGFR of 80.718.7 mL/
min/1.73 m2 (Table 1). Distribution of WMH score was right-
skewed, with a median score of 4 (interquartile range, 2–8).
Sixty-three percent of participants were male, 51% were
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white, 31% had a history diabetes mellitus, and 75% had a
history of hypertension. Persons in the highest tertile of WMH
were older (mean age, 67.310.8 years), were more likely to
have hypertension (82%), and had lower eGFR (74.818.3).
History of previous lacunar stroke (16%) and eGFR <60 mL/
min/1.73 m2 (24%) were also most prevalent in the highest
WMH tertile. Participants excluded from our cross-sectional
and stroke analyses were more likely to be male, more likely
to be white, had lower eGFR, and had a higher proportion of
persons with history of lacunar stroke before the presenting
stroke compared with included (Table S1). The 566 partici-
pants excluded in our analysis of kidney outcomes had a
lower SBP, a smaller proportion of Hispanics and former
smokers, and a higher proportion of blacks, whites, current
smokers, and persons with history of lacunar stroke before
the presenting stroke compared with included (Table S2).
WMHs and eGFR at Baseline
WMH score had a significant inverse association with baseline
kidney function. Unadjusted linear regression demonstrated
that each point higher in WMH score corresponded to 1.01
(95% CI, 0.85–1.17) mL/min/1.73 m2 lower in eGFR, on
average. Adjustment for age, sex, and race slightly attenuated
the association. After further adjustment for additional
traditional chronic kidney disease risk factors and antihyper-
tensive therapy, each point higher in WMH score corre-
sponded to 0.36 (95% CI, 0.18–0.50) mL/min/1.73 m2 lower
baseline eGFR.
WMHs and Kidney Function Decline After
Intensive BP Control
In the first year after randomization, 100 of the 1236 (8.1%)
included participants in the higher-target arm experienced
rapid kidney function decline, compared with 134 of the 1218
(11.0%) in the lower-target arm (odds ratio=1.40; 95% CI,
1.07–1.84). These findings were similar to those of previous
analyses.5
The effect of intensive BP lowering on rapid kidney function
decline appeared to intensify with increasing WMH score,
suggesting an interaction between BP target and WMH score
(FigureA). Specifically, within the lowest WMH tertile, there
were 26% higher odds of rapid kidney function decline in the
lower-target group compared with the higher-target group,
whereas the odds were 34% higher in the lower-target group
compared with the higher-target group within the middle
WMH tertile, and the odds were 71% higher in the lower-target
group compared with the higher-target group within the
highest WMH tertile (Table 2). A test for interaction, however,
did not indicate statistically significant interaction by WMH
score (P=0.65). Similarly, average kidney function decline in
the lower-target group was 1.49 (95% CI, 0.35 to 3.33) mL/
min/1.73 m2 faster than in the higher-target group among
persons in the lowest WMH tertile, whereas average decline
was 2.17 (95% CI, 0.12 to 4.46) mL/min/1.73 m2 faster in
the lower-target group among persons in the middle WMH
tertile and 2.56 (95% CI, 0.36 to 4.77) mL/min/1.73 m2
faster in the lower-target group among persons in the highest
WMH tertile. A formal test for interaction did not indicate
statistically significant interaction by WMH on mean kidney
function decline (P=0.17).
WMHs and Stroke After Intensive BP Control
Overall incidence of recurrent stroke was 7.9% in the lower-
target arm and 9.6% in the higher-target arm (hazard
ratio=0.80; 95% CI, 0.63–1.03). These findings were similar
to those in past analyses.2 Persons in the highest WMH tertile
had the highest overall stroke incidence (12.3%), but they also
had the largest absolute reduction in stroke incidence from
intensive BP lowering (3.4%; Table 3). Within the lowest WMH
tertile, the hazard ratio for stroke recurrence in the lower BP
target arm compared with the higher-target arm was 1.13
(95% CI, 0.73–1.75) compared with a hazard ratio of 0.73
(95% CI, 0.49–1.09) within the highest WMH tertile. Kaplan–
Meier plots of stroke within tertiles of WMH score are
depicted in Figure S1. A test for interaction indicated
significant interaction between WMH score and the intensive
BP intervention for the outcome of stroke (P=0.04), that is,
intensive BP lowering provided greater stroke prevention in
those with higher WMH burden (FigureB).
Discussion
In our secondary analyses of the SPS3 trial, we found that
higher white matter disease burden was independently
associated with lower baseline eGFR. We also found that
degree of WMH burden, a marker of cerebral small vessel
disease, may identify persons at highest risk for rapid kidney
function decline from intensive BP lowering; however, this
interaction was not statistically significant. Additionally, we
observed that a higher WMH score distinguished persons who
derive the highest benefit from aggressive BP lowering to
reduce risk for recurrent stroke. Our findings suggest that
WMH, a marker of microvascular disease in the brain, may
identify subgroups of persons with different benefits and risk
from intensive BP lowering. Specifically, although persons
with a higher burden of microvascular disease may be at
higher risk for rapid kidney function decline from aggressive
BP lowering, they also appear most likely to benefit in
secondary stroke prevention.
This study supports previous literature describing an
independent association between cerebrovascular disease
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and lower kidney function levels.14 In our study, this associ-
ation was demonstrated to be independent of age, sex, race,
and other vascular risk factors. This study also contributes to a
much smaller body of literature investigating the relationship
between cerebrovascular disease and change in kidney
function over time, here, in the context of BP lowering.21,22
We and others have shown that intensive BP lowering
results in increased risk for rapid kidney function decline
Table 1. Baseline Clinical and Demographic Characteristics of Secondary Prevention of Small Subcortical Strokes Trial
Participants by Tertile of WMH Score
Characteristic
Lowest Tertile (n=1210) Middle Tertile (n=937) Highest Tertile (n=820) Total (N=2967)
No. or Mean (%) or (SD) No. or Mean (%) or (SD) No. or Mean (%) or (SD) No. or Mean (%) or (SD)
Age, y 59.3 (10.0) 63.3 (10.1) 67.3 (10.8) 62.8 (10.8)
Male* 785 (64.9) 591 (63.1) 485 (59.1) 1861 (62.7)
Race†
White 635 (52.5) 483 (51.5) 386 (47.1) 1504 (50.7)
Hispanic 373 (30.8) 273 (29.1) 257 (31.3) 903 (30.4)
Black 170 (14.0) 160 (17.1) 156 (19.0) 486 (16.4)
Other 32 (2.6) 21 (2.2) 21 (2.6) 74 (2.5)
Smoking
Never 506 (41.8) 344 (36.7) 325 (39.6) 1175 (39.6)
Former 458 (37.9) 384 (41.0) 343 (41.8) 1185 (39.9)
Current 246 (20.3) 209 (22.3) 152 (18.5) 607 (20.5)
Diabetes mellitus 407 (33.6) 330 (35.2) 252 (30.7) 989 (33.3)
History of hypertension† 832 (68.8) 716 (76.4) 676 (82.4) 2224 (75.0)
Antihypertensive use† 971 (80.2) 802 (85.6) 739 (90.1) 2512 (84.7)
ACE inhibitor or ARB use
At baseline† 765 (63.2) 636 (67.9) 587 (71.6) 1988 (67.0)
At 1-year follow-up 688 (67.9) 569 (73.9) 504 (75.1) 1761 (71.8)
Statin use 832 (68.8) 662 (70.7) 549 (67.0) 2043 (68.9)
Previous lacunar stroke†
Yes 61 (5.0) 107 (11.4) 132 (16.1) 300 (10.1)
Missing 2 (0.2) 1 (0.1) 0 (0.0) 3 (0.1)
Total cholesterol, mg/dL 189.8 (48.3) 187.1 (47.1) 185.9 (45.4) 187.9 (47.2)
High-density lipoprotein
cholesterol, mg/dL
44.7 (19.6) 45.4 (20.1) 46.6 (14.2) 45.4 (18.5)
Systolic blood pressure, mm Hg† 140.1 (17.3) 143.2 (18.9) 147.3 (20.2) 143.0 (18.9)
Body mass index, kg/m2† 29.7 (7.9) 29.1 (6.2) 28.1 (5.8) 29.1 (6.9)
eGFR, mL/min/1.73 m2† 84.8 (18.2) 80.6 (19.0) 74.8 (18.3) 80.7 (18.9)
eGFR <60, mL/min/1.73 m2 114 (9.4) 145 (15.5) 195 (23.8) 454 (15.3)
eGFR 60 to 90, mL/min/1.73 m2 583 (48.2) 473 (50.5) 445 (54.3) 1501 (50.6)
eGFR >90, mL/min/1.73 m2 513 (42.4) 319 (34.0) 180 (22.0) 1012 (34.1)
WMH score† 1.8 (1.0) 5.4 (1.1) 11.0 (2.9) 5.5 (4.1)
Randomized to systolic
blood pressure target <130 mm Hg
626 (51.7) 471 (50.3) 381 (46.5) 1478 (49.8)
Differences in distribution of categorical variables and means of continuous variables tested using chi-squared and ANOVA, respectively. Follow-up data from 2454 participants with
baseline WMH score and creatinine measure at 1-year follow-up. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration
rate; WMH, white matter hyperintensity.
*P for statistical test <0.05.
†
P<0.0005.
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compared with higher BP target.3–5 Our study extends these
findings by showing that WMHs, a marker of cerebral small-
vessel disease, may identify persons most likely to have
creatinine elevation with intensive BP lowering. To our
knowledge, this is 1 of very few studies to investigate the
effectiveness of intensive BP lowering for prevention of stroke
within subgroups defined by level of white matter disease in
the brain.11,23 Several previous studies have demonstrated an
elevated risk of incident and recurrent stroke in those with
higher levels of white matter disease.10 Our analysis showed
those with higher levels of white matter disease may have a
greater reduction in stroke recurrence from intensive BP
lowering. The larger absolute benefit may be explained by this
population’s higher absolute risk.
Taken together, our findings could be explained by a
common mechanism, such as impaired small-vessel autoreg-
ulation in the brain and kidney among persons with higher
burden of WMH. Both the brain and kidney are perfused by
low-resistance vascular beds with small vessels that rely on
strict autoregulation to manage hemodynamic stress from
large supplying arteries.15,24 It is plausible that WMHs identify
a vascular phenotype with less autoregulatory reserve to
manage long-term hemodynamic stress, whether it is from
hypertension or intensive BP lowering.
Alternatively, the findings of greater stroke prevention and
possibly greater increase in kidney function decline could be
explained by the effects of renin-angiotensin system blockade
in the kidney and cerebral vasculature. Participants in higher
WMH tertiles of our study had more-prevalent use of
angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers at baseline and 1-year follow-up (Table 1).
We have previously shown that angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers were
commonly added to achieve BP targets in SPS3.5 Excessive
renin-angiotensin system pathway blockade has been shown
to be harmful to kidney function in previous trials.25,26 On the
other hand, renin-angiotensin system blockade has also been
shown to have protective effects in cerebral tissue during
Figure. Effect of intensive vs usual systolic blood pressure target on rapid eGFR decline and recurrent stroke among persons across the range
of brain magnetic resonance imaging WMH scores. Plotted lines depict predicted rates of rapid kidney function decline (A) and recurrent stroke
(B) in higher-target (solid line) and lower-target (dashed line) arms. Markers depict observed rates of rapid decline and recurrent stroke in higher
target (white squares) and lower-target (black square) groups within each WMH score. Predictions based on logistic regression (rapid decline)
and Cox regression (recurrent stroke) models. eGFR indicates estimated glomerular filtration rate; WMH, white matter hyperintensity.
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ischemic injury.27,28 This could explain greater stroke pre-
vention from intensive BP lowering at the expense of kidney
function in our population of nonproteinuric persons with
elevated stroke risk.
We do not believe that our findings can be attributed to the
association between higher WMH burden and lower eGFR,
because we have previously reported that the effect of a lower
BP target increasing eGFR decline is more pronounced at
higher baseline eGFR levels.5 This makes it unlikely that
participants with higher WMH burden had more kidney
function decline from intensive BP lowering because of their
baseline eGFR, which we found in this study to be lower.
The clinical significance of rapid kidney function decline in
the context of intensive BP lowering remains uncertain. Our
previous work showed no association of rapid eGFR function
decline with adverse outcomes in the setting of intensive BP
lowering.5 It has also been demonstrated that intensive BP
lowering was not associated with higher levels of tubular
kidney injury markers in a primary prevention trial of intensive
BP lowering, even among those with increases in serum
creatinine.8,29 This suggests that rapid kidney function decline
after intensive BP lowering may primarily represent a
hemodynamic effect. It has also been demonstrated that
most acute kidney injury in a trial of intensive BP lowering is
mild and reversible.30 Nevertheless, we believe this outcome
is important because rapid kidney function decline may cause
clinicians to withdraw potentially beneficial antihypertensive
therapy.
Table 2. Association of Usual Versus Intensive SBP Target With Rapid eGFR Decline in the First Year by WMH Tertile Among 2454
SPS3 Trial Participants
SBP Target, mm Hg Events Odds Ratio (95% CI) P Value*
Lowest WMH tertile (n=1013)
130 to 149 36/498 7.2% Referent
<130 46/515 9.0% 1.26 (0.80–1.98) 0.32
Medium WMH tertile (n=770)
130 to 149 33/381 8.7% Referent
<130 44/389 11.3% 1.34 (0.84–2.16) 0.22
Highest WMH tertile (n=671)
130 to 149 31/357 8.7% Referent
<130 44/314 14.0% 1.71 (1.05–2.80) 0.03
P for interaction=0.65. eGFR indicates estimated glomerular filtration rate; SBP, systolic blood pressure; SPS3, Secondary Prevention of Small Subcortical Strokes; WMH, white matter
hyperintensity.
*P value for OR within WMH tertile.
Table 3. Effect of Intensive Blood Pressure Lowering on Recurrent Stroke, Stratified by WMH Score in 2967 Participants of
Secondary Prevention of Small Subcortical Strokes Trial
Systolic Blood Pressure Target, mm Hg Events Hazard Ratio (95% CI) P Value*
Lowest WMH tertile (n=1210)
130 to 149 37/584 6.3% Referent
<130 44/626 7.0% 1.13 (0.73–1.75) 0.589
Medium WMH tertile (n=937)
130 to 149 45/466 9.7% Referent
<130 32/471 6.8% 0.67 (0.43–1.06) 0.089
Highest WMH tertile (n=820)
130 to 149 61/439 13.9% Referent
<130 40/381 10.5% 0.73 (0.49–1.09) 0.123
Included participants analyzed based on intention to treat. Median follow-up durations in the lowest, medium, and highest WMH tertiles were 3.7, 3.3, and 3.4 years, respectively. P for
interaction=0.04. WMH indicates white matter hyperintensity.
*P value for hazard ratio within WMH tertile.
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The randomized-controlled design of SPS3 is a key
strength of this study, which facilitated investigation into
the benefit and harm of intensive BP control. Investigating
WMH as a predictor of kidney function decline is novel. It is
also very generalizable to the clinical assessment of stroke
patients and their prognosis. Additionally, our longitudinal
outcome of kidney function decline offers more-dynamic
information about the relationship between cerebrovascular
disease and kidney function than is available from
previously utilized cross-sectional analyses. Our outcome
of 1-year kidney function decline may have been too soon
after enrollment to observe statistically significant interac-
tions between WMHs and intensive BP lowering with
respect to kidney function decline. Additionally, the exclu-
sion of 566 participants in our longitudinal analysis
introduces the possibility of bias that could also have
affected our results. Despite these limitations and the lack
of statistical significance in some of our results, we believe
these results of our analyses serve well to generate
hypotheses about shared mechanisms of brain and kidney
vascular injury.
Future research should be directed at further determining
the significance of cerebrovascular disease regarding renal
and cardiovascular outcomes. Other identifiable features of
small-vessel cerebrovascular disease, including silent brain
infarcts or cerebral microbleeds, may prove to be useful
predictors of renal and cardiovascular outcomes. With longer
follow-up than available in the present study, the association
of white matter hyperintensities and other markers of small-
vessel disease in the brain with long-term kidney function
decline could also be further elucidated. In addition, studying
the effect of intensive BP lowering in a population with
proteinuria may offer additional insight toward its relative
benefit and harm in the context of different cardiovascular
risk profiles.
In summary, higher WMH burden was associated with
lower baseline eGFR, which supports the notion of shared
vascular injury mechanisms. Burden of WMHs might be able
identify persons at increased risk of rapid kidney function
decline from intensive BP lowering, though this interaction
was not statistically significant. Interestingly, those with
high WMH burden were also most likely to benefit from
intensive BP lowering to prevent stroke recurrence. Larger
studies are required to replicate these findings.
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SUPPLEMENTAL MATERIAL
Table S1. Baseline characteristics of Secondary Prevention of Small Subcortical 
Strokes trial participants included and excluded in cross-sectional analysis. 
Characteristic Included (n=2,967) Excluded (n=53) Total (n=3,020) 
No. or 
mean 
(% or SD) No. or 
mean 
(% or SD) No. or 
mean 
(% or SD) 
Age, years 62.8 (10.8) 64.3 (10.2) 62.8 (10.8) 
Male* 1,861 (62.7) 41 (77.4) 1,902 (63.0) 
Race 
White 1,504 (50.7) 34 (64.2) 1,538 (50.9) 
Hispanic 903 (30.4) 13 (24.5) 916 (30.3) 
Black 486 (16.4) 6 (11.3) 492 (16.3) 
Other 74 (2.5) 0 (0.0) 74 (2.5) 
Smoking 
Never 1,175 (39.6) 21 (39.6) 1,196 (39.6) 
Former 1,185 (39.9) 22 (41.5) 1,207 (40.0) 
Current 607 (20.5) 10 (18.9) 617 (20.4) 
Diabetes 989 (33.3) 13 (24.5) 1,002 (33.2) 
History of hypertension 2,224 (75.0) 40 (75.5) 2,264 (75.0) 
Antihypertensive use 2,512 (84.7) 45 (84.9) 2,557 (84.7) 
ACE-inhibitor or ARB use 1,988 (67.0) 39 (73.6) 2,027 (67.1) 
Statin use 2,043 (68.9) 38 (71.7) 2,081 (68.9) 
Prior lacunar stroke** 
Yes 300 (10.1) 8 (15.1) 308 (10.2) 
Missing 3 (0.1) 2 (3.8) 5 (0.2) 
Total cholesterol, mg/dL 187.9 (47.2) 192.3 (42.2) 187.9 (47.1) 
High-density lipoprotein 
cholesterol, mg/dL 
45.4 (18.5) 42.7 (11.7) 45.4 (18.4) 
Systolic blood pressure 143.0 (18.9) 141.0 (14.4) 143.0 (18.8) 
Body mass index, kg/m2 29.1 (6.9) 28.7 (5.1) 29.1 (6.8) 
eGFR, mL/min/1.73m2* 80.7 (18.9) 74.7 (19.5) 80.6 (18.9) 
eGFR <60 454 (15.3) 11 (20.8) 465 (15.4) 
eGFR 60-90 1,501 (50.6) 26 (49.1) 1,527 (50.6) 
eGFR >90 1,012 (34.1) 13 (24.5) 1,025 (33.9) 
Missing 0 (0.0) 3 (5.7) 3 (0.1) 
White matter 
hyperintensities score 
5.5 (4.1) 2.0 (0.0) 5.5 (4.1) 
Missing 0 (0.0) 50 (94.3) 50 (1.7) 
Systolic blood pressure 
target <130 
1,478 (49.8) 23 (43.4) 1,501 (49.7) 
Differences in distribution of categorical variables and means of continuous variables tested using chi-
squared and t-test, respectively. * = p for statistical test < 0.05, ** = p <0.0005.  SD = standard deviation, 
ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, eGFR = estimated 
glomerular filtration rate 
Table S2. Baseline characteristics of Secondary Preventions of Small Subcortical 
Strokes trial participants included and excluded in longitudinal analysis.
Characteristic Included (n=2,454) Excluded (n=566) Total (N=3,020) 
No. or 
mean 
(%) or 
(SD) 
No. or 
mean 
(%) or 
(SD) 
No. or 
mean 
(%) or 
(SD) 
Age 62.9 (10.7) 62.1 (11.2) 62.8 (10.8) 
Male 1,557 (63.4) 345 (61.0) 1,902 (63.0) 
Race** 
White 1,218 (49.6) 320 (56.5) 1,538 (50.9) 
Hispanic 801 (32.6) 115 (20.3) 916 (30.3) 
Black 375 (15.3) 117 (20.7) 492 (16.3) 
Other 60 (2.4) 14 (2.5) 74 (2.5) 
Smoking* 
Never 974 (39.7) 222 (39.2) 1,196 (39.6) 
Former 1,007 (41.0) 200 (35.3) 1,207 (40.0) 
Current 473 (19.3) 144 (25.4) 617 (20.4) 
Diabetes 808 (32.9) 194 (34.3) 1,002 (33.2) 
History of hypertension 1,835 (74.8) 429 (75.8) 2,264 (75.0) 
Antihypertensive use 2,079 (84.7) 478 (84.5) 2,557 (84.7) 
ACE inhibitor or ARB use 1,663 (67.8) 364 (64.3) 2,027 (67.1) 
Statin use 1,675 (68.3) 406 (71.7) 2,081 (68.9) 
Prior lacunar stroke* 
Yes 243 (9.9) 65 (11.5) 308 (10.2) 
Missing 2 (0.1) 3 (0.5) 5 (0.2) 
Total cholesterol, mg/dL 187.2 (46.2) 191.1 (50.6) 187.9 (47.1) 
High-density lipoprotein 
cholesterol, mg/dL 
45.4 (18.3) 45.4 (19.0) 45.4 (18.4) 
Systolic blood pressure, mmHg* 142.6 (18.7) 144.6 (19.3) 143.0 (18.8) 
Body mass index, kg/m2 29.1 (7.0) 29.0 (6.0) 29.1 (6.8) 
eGFR, mL/min/1.73m2 80.6 (18.6) 80.7 (20.1) 80.6 (18.9) 
eGFR <60 367 (15.0) 98 (17.3) 465 (15.4) 
eGFR 60-90 1259 (51.3) 268 (47.3) 1527 (50.6) 
eGFR >90 828 (33.7) 197 (34.8) 1025 (33.9) 
Missing 0 (0.0) 3 (0.5) 3 (0.1) 
White matter hyperintensity score 5.4 (4.1) 5.8 (4.2) 5.5 (4.1) 
SBP goal <130 1,218 (49.6) 283 (50.0) 1,501 (49.7) 
Differences in distribution of categorical variables and means of continuous variables tested using chi-
squared and t-test, respectively. * = p for comparison < 0.05, ** = p <0.0005.  SD = standard deviation, 
ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, eGFR = estimated 
glomerular filtration rate. 
Figure S1. Kaplan-Meier estimates of probability of recurrent stroke among 
persons randomized to higher vs. lower BP target, stratified by WMH tertile. 
WMH = white matter hyperintensities, SBP = systolic blood pressure. 
